All In Biotech

Free tool

FAERS Monitor: Filsuvez

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 215064 or its brand name (Filsuvez, Birch Triterpenes). Reports on generic versions are filed under their own applications.

Reports

276

Serious

54

20% of reports

Hospitalization

26

Death reported

13

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • wound complication43
  • wound41
  • product dose omission issue40
  • product use issue38
  • wrong technique in product usage process26
  • drug ineffective25
  • off label use24
  • product administration interrupted24
  • treatment noncompliance18
  • blister17
  • pruritus15
  • wound secretion15
  • wound infection14
  • product complaint13
  • impaired healing12

Reports by year received

View as table
YearReports
202453
2025102
2026121

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,883 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
wound complicationSignal43967.0733.340,035
wound secretionSignal15293.0179.04,063
product administration interruptedSignal24233.7159.45,317
woundSignal41111.984.44,397
wound infectionSignal1497.658.51,242
product complaintSignal1339.123.0446
impaired healingSignal1227.916.0285
treatment noncomplianceSignal1825.116.0393
blisterSignal1723.114.6338
product use issueSignal3815.411.5502
product dose omission issueSignal4010.47.8334
wrong technique in product usage processSignal269.86.8198
pruritusSignal153.01.818
off label useSignal242.11.413
drug ineffective251.41.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.